Together, the major limitations of these clinical studies are their small patient group size and the use of relatively unspecific P-gp inhibitors (e.g., verapamil), and thus, no firm conclusion about the efficacy of add-on P-gp inhibitors in refractory epilepsy can be drawn at present. This evidence concerns the gene PGP and epilepsy.